Publications by authors named "Gaurav Syal"

Claim this Profile
C
Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis.
Siddharth Singh, M Hassan Murad, Yuhong Yuan, Ashwin N Ananthakrishnan, Benjamin Click, Gaurav Syal

Gastroenterology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease.
Frank I Scott, Ashwin N Ananthakrishnan, Benjamin Click, Manasi Agrawal, Gaurav Syal

Gastroenterology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists.
Han Hee Lee, Virginia Solitano, Sujay Singh, Ashwin N Ananthakrishnan, Vipul Jairath, Gaurav Syal

Clin Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-23p19 Antagonists vs Ustekinumab for Treatment of Crohn's Disease: A Meta-Analysis of Randomized Controlled Trials.
Claudia Dziegielewski, Yuhong Yuan, Christopher Ma, Brigid S Boland, John T Chang, Gaurav Syal

Am J Gastroenterol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost Effectiveness of the 8-Strain Probiotic in Primary and Secondary Prophylaxis of Pouchitis.
Gaurav Syal, Siddharth Singh, Edward L Barnes

Gastro Hep Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis.
Dhruv Ahuja, Guangyong Zou, Virginia Solitano, Gaurav Syal, Han Hee Lee

Clin Gastroenterol Hepatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis.
Punya Chittajallu, Gaurav Syal

Dig Dis Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Communicating Information Regarding IBD Remission to Patients: Evidence From a Survey of Adult Patients in the United States.
Dallas W Wood, Katherine Treiman, Aileen Rivell, Welmoed K van Deen, Hilary Heyison, Gaurav Syal

Inflamm Bowel Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing Pouchitis: Where do Antibiotics End, and Advanced Therapies Begin?
Arpita Jajoo, Shahrad Hakimian, Gaurav Syal

Curr Gastroenterol Rep· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naïve Patients With Ulcerative Colitis.
Austin Haynesworth, Kuan-Hung Yeh, Han Hee Lee, Melissa Kirkpatrick, Brigid S Boland, Gaurav Syal

Aliment Pharmacol Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis.
Gaurav Syal, Edward Barnes, Laura Raffals, Elie Al Kazzi, John Haydek

Am J Gastroenterol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium.
Andres J Yarur, Ryan Ungaro, Katherine Huang, Wenfei Wang, Priya Sasankan, Gaurav Syal

Inflamm Bowel Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis.
Gaurav Syal, Edward Barnes, Laura Raffals, Elie Al Kazzi, John Haydek

Am J Gastroenterol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Oral Tofacitinib in Chronic Pouchitis: A Prospective, Open-Label Pilot Study.
Gaurav Syal, Daniel S Mishkin, Andrea Banty, Susie Lee, Norma Fontelera

Inflamm Bowel Dis· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Association Analyses of Extraintestinal Manifestations in Inflammatory Bowel Disease.
Michelle Khrom, Millie Long, Shishir Dube, Lori Robbins, Gregory J Botwin, Gaurav Syal

Gastroenterology· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ileal Paneth Cell Phenotype is a Cellular Biomarker for Pouch Complications in Ulcerative Colitis.
Changqing Ma, Talin Haritunians, Anas K Gremida, Gaurav Syal, Janaki Shah

J Crohns Colitis· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Treatment Response on Risk of Serious Infections in Patients With Crohn's Disease: Secondary Analysis of the PYRAMID Registry.
Dhruv Ahuja, Jiyu Luo, Yuchen Qi, Gaurav Syal, Brigid S Boland

Clin Gastroenterol Hepatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-operative visceral adipose tissue radiodensity is a potentially novel prognostic biomarker for early endoscopic post-operative recurrence in Crohn's disease.
Phillip Gu, Shishir Dube, Norman Gellada, So Yung Choi, Susan Win, Gaurav Syal

World J Gastrointest Surg· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.
David J Katibian, Virginia Solitano, D Brent Polk, Tran Nguyen, Christopher Ma, Gaurav Syal

Clin Gastroenterol Hepatol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn's Disease (CD).
Phillip Gu, Shishir Dube, YooJin Lee, Shaohong Yang, Dalin Li, Gaurav Syal

Dig Dis Sci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders.
Edward L Barnes, Manasi Agrawal, Gaurav Syal, Ashwin N Ananthakrishnan, Benjamin L Cohen

Gastroenterology· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
Marzieh Akhlaghpour, Talin Haritunians, Shyam K More, Lisa S Thomas, Dalton T Stamps, Gaurav Syal

Gut· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' Perspectives, Experiences, and Concerns With Perianal Fistulae: Insights From Online Targeted-Disease Forums.
Carine Khalil, Welmoed K van Deen, Taylor Dupuy, Gaurav Syal, Corey Arnold

Crohns Colitis 360· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
Siddharth Singh, Jihoon Kim, Jiyu Luo, Paulina Paul, Vivek Rudrapatna, Gaurav Syal

Clin Gastroenterol Hepatol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Gaurav Syal, Gil Y Melmed, Christopher V Almario, Brennan M R Spiegel

Dig Dis Sci· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis